Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase 1 open label, first in human trial to study safety and tolerability of NK-T cells combined with vvDD: An accelerated dose escalation in multiple tumor types. Dorigo, O., Contag, P., Moser, J., Patel, S., Frohlich, M. W. AMER ASSOC CANCER RESEARCH. 2022
View details for Web of Science ID 000892509502098